JP6742905B2 - 治療活性のある化合物及びその使用方法 - Google Patents

治療活性のある化合物及びその使用方法 Download PDF

Info

Publication number
JP6742905B2
JP6742905B2 JP2016531940A JP2016531940A JP6742905B2 JP 6742905 B2 JP6742905 B2 JP 6742905B2 JP 2016531940 A JP2016531940 A JP 2016531940A JP 2016531940 A JP2016531940 A JP 2016531940A JP 6742905 B2 JP6742905 B2 JP 6742905B2
Authority
JP
Japan
Prior art keywords
compound
dose
idh2
crystalline form
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016531940A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527279A5 (enExample
JP2016527279A (ja
Inventor
ブイ．アグレスタ サムエル
ブイ．アグレスタ サムエル
グ チョング‐フイ
グ チョング‐フイ
スチェンケイン デビッド
スチェンケイン デビッド
ヤング フア
ヤング フア
グオ リトイング
グオ リトイング
タング ズヘン
タング ズヘン
ワング ジアンミング
ワング ジアンミング
ズハング ヤンフェング
ズハング ヤンフェング
ズホウ ヤン
ズホウ ヤン
Original Assignee
アギオス ファーマシューティカルス，インコーポレーテッド
アギオス ファーマシューティカルス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2013/081170 external-priority patent/WO2015018060A1/en
Application filed by アギオス ファーマシューティカルス，インコーポレーテッド, アギオス ファーマシューティカルス，インコーポレーテッド filed Critical アギオス ファーマシューティカルス，インコーポレーテッド
Publication of JP2016527279A publication Critical patent/JP2016527279A/ja
Publication of JP2016527279A5 publication Critical patent/JP2016527279A5/ja
Application granted granted Critical
Publication of JP6742905B2 publication Critical patent/JP6742905B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2016531940A 2013-08-02 2014-08-01 治療活性のある化合物及びその使用方法 Active JP6742905B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201361861884P 2013-08-02 2013-08-02
US61/861,884 2013-08-02
PCT/CN2013/081170 WO2015018060A1 (en) 2013-08-09 2013-08-09 Crystalline forms of therapeutically active compounds and use thereof
CNPCT/CN2013/081170 2013-08-09
US201461939098P 2014-02-12 2014-02-12
US61/939,098 2014-02-12
US201461975448P 2014-04-04 2014-04-04
US61/975,448 2014-04-04
US201462011948P 2014-06-13 2014-06-13
US62/011,948 2014-06-13
PCT/US2014/049469 WO2015017821A2 (en) 2013-08-02 2014-08-01 Therapeutically active compounds and their methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019082794A Division JP2019142930A (ja) 2013-08-02 2019-04-24 治療活性のある化合物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2016527279A JP2016527279A (ja) 2016-09-08
JP2016527279A5 JP2016527279A5 (enExample) 2017-09-07
JP6742905B2 true JP6742905B2 (ja) 2020-08-19

Family

ID=52432592

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016531940A Active JP6742905B2 (ja) 2013-08-02 2014-08-01 治療活性のある化合物及びその使用方法
JP2019082794A Withdrawn JP2019142930A (ja) 2013-08-02 2019-04-24 治療活性のある化合物及びその使用方法
JP2021123814A Pending JP2021176893A (ja) 2013-08-02 2021-07-29 治療活性のある化合物及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019082794A Withdrawn JP2019142930A (ja) 2013-08-02 2019-04-24 治療活性のある化合物及びその使用方法
JP2021123814A Pending JP2021176893A (ja) 2013-08-02 2021-07-29 治療活性のある化合物及びその使用方法

Country Status (21)

Country Link
US (6) US9738625B2 (enExample)
EP (3) EP3027193A4 (enExample)
JP (3) JP6742905B2 (enExample)
CN (3) CN105916507A (enExample)
AU (2) AU2014295938B2 (enExample)
BR (1) BR112016002287A2 (enExample)
CA (1) CA2919382A1 (enExample)
CL (2) CL2016000263A1 (enExample)
EA (1) EA030428B1 (enExample)
ES (1) ES2886211T3 (enExample)
IL (2) IL243833A0 (enExample)
MX (2) MX389250B (enExample)
MY (1) MY177994A (enExample)
NI (1) NI201600022A (enExample)
PE (1) PE20160840A1 (enExample)
PH (1) PH12016500164B1 (enExample)
SA (1) SA516370523B1 (enExample)
SG (2) SG10201709187TA (enExample)
TW (2) TWI666208B (enExample)
UA (1) UA121021C2 (enExample)
WO (1) WO2015017821A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105916507A (zh) 2013-08-02 2016-08-31 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
AU2015324158A1 (en) * 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20180134683A1 (en) * 2015-05-07 2018-05-17 Teligene Ltd. Heterocylcic compounds as idh2 inhibitors
AU2016299092B2 (en) 2015-07-30 2020-08-20 Centaurus Biopharma Co., Ltd. 1, 3, 5-triazine derivative and method of using same
CN108349933A (zh) 2015-08-05 2018-07-31 安吉奥斯医药品有限公司 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法
JP2018534288A (ja) 2015-10-15 2018-11-22 アジオス ファーマシューティカルズ， インコーポレイテッド 悪性腫瘍の治療のための併用療法
CA3002029A1 (en) * 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
JP6588647B2 (ja) * 2015-10-21 2019-10-09 ノイフォルム・ファーマシューティカルズ・インコーポレイテッドＮｅｕｆｏｒｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 血液悪性腫瘍を治療するための重水素化合物及びその組成物並びに方法
MA43374A (fr) * 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
CA3015753A1 (en) * 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
WO2018026894A1 (en) 2016-08-03 2018-02-08 Celgene Corporation Methods of treatment of myelodysplastic syndrome
JP7093764B2 (ja) * 2016-08-03 2022-06-30 セルジーン コーポレイション 骨髄異形成症候群の治療方法
KR102498693B1 (ko) * 2016-09-07 2023-02-10 셀진 코포레이션 정제 조성물
JP7111725B2 (ja) * 2017-01-22 2022-08-02 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 １，３，５－トリアジン誘導体の塩およびその結晶、その製造方法、医薬組成物、ならびにそれらの使用
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
EP4201399A3 (en) 2017-06-30 2023-08-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
US20220401450A1 (en) 2019-11-14 2022-12-22 Celgene Corporation Pediatric formulations for treatment of cancer
CN114773320A (zh) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-三嗪化合物及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
DE59106971D1 (de) 1990-07-12 1996-01-11 Ciba Geigy Ag Verfahren zur photochemischen und thermischen Stabilisierung von Polyamid-Fasermaterialien.
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
WO2000075129A1 (en) 1999-06-07 2000-12-14 Shire Biochem Inc. Thiophene integrin inhibitors
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
SI2256108T1 (sl) 2002-07-18 2016-05-31 Janssen Pharmaceutica N.V. Substituirani triazinski kinazni inhibitorji
WO2008131547A1 (en) * 2007-04-30 2008-11-06 Prometic Biosciences Inc. 'triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives'
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
CA2764785C (en) * 2009-06-08 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
CA2767008C (en) * 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
SMT201800334T1 (it) * 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
MX375030B (es) 2013-07-11 2025-03-06 Agios Pharmaceuticals Inc Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.
CN105916507A (zh) * 2013-08-02 2016-08-31 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
AU2015324158A1 (en) 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3253746A1 (en) 2015-02-04 2017-12-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
TW201932455A (zh) 2019-08-16
MX2016001361A (es) 2016-06-14
CA2919382A1 (en) 2015-02-05
EA030428B1 (ru) 2018-08-31
EP3566706A1 (en) 2019-11-13
PE20160840A1 (es) 2016-09-22
ES2886211T3 (es) 2021-12-16
AU2014295938B2 (en) 2018-07-19
US20180370951A1 (en) 2018-12-27
MX394658B (es) 2025-03-24
EA201690322A1 (ru) 2016-07-29
NI201600022A (es) 2016-03-16
EP3027193A2 (en) 2016-06-08
JP2019142930A (ja) 2019-08-29
SG11201600479WA (en) 2016-02-26
SA516370523B1 (ar) 2019-01-10
US10730854B2 (en) 2020-08-04
NZ716226A (en) 2021-08-27
EP3932408A1 (en) 2022-01-05
IL243833A0 (en) 2016-04-21
US20240132474A1 (en) 2024-04-25
AU2018247242B2 (en) 2020-03-12
MX389250B (es) 2025-03-20
EP3027193A4 (en) 2017-04-26
BR112016002287A2 (pt) 2017-08-01
US20210155603A1 (en) 2021-05-27
CN110386922A (zh) 2019-10-29
IL270347B (en) 2021-08-31
US20260085059A1 (en) 2026-03-26
CN110372670A (zh) 2019-10-25
CN105916507A (zh) 2016-08-31
US10093654B2 (en) 2018-10-09
WO2015017821A3 (en) 2015-04-09
JP2021176893A (ja) 2021-11-11
EP3566706B1 (en) 2021-07-14
UA121021C2 (uk) 2020-03-25
CN110372670B (zh) 2023-04-07
CL2016000263A1 (es) 2016-08-19
TW201524971A (zh) 2015-07-01
US9738625B2 (en) 2017-08-22
US20170305885A1 (en) 2017-10-26
AU2018247242A1 (en) 2018-11-01
TWI666208B (zh) 2019-07-21
MX2020011397A (es) 2022-08-05
PH12016500164A1 (en) 2016-04-25
MY177994A (en) 2020-09-28
WO2015017821A2 (en) 2015-02-05
AU2014295938A1 (en) 2016-02-18
SG10201709187TA (en) 2017-12-28
JP2016527279A (ja) 2016-09-08
PH12016500164B1 (en) 2023-11-08
US20160194305A1 (en) 2016-07-07
CL2017002240A1 (es) 2018-04-20
TWI701242B (zh) 2020-08-11

Similar Documents

Publication Publication Date Title
US20260085059A1 (en) Therapeutically active compounds and their methods of use
JP7220986B2 (ja) 治療効果のある化合物及びその使用方法
KR102316886B1 (ko) 치료학적 활성 화합물 및 이의 사용방법
HK40016190A (en) Therapeutically active compounds and their methods of use
HK40016189A (en) Therapeutically active compounds and their methods of use
HK40016189B (en) Therapeutically active compounds and their methods of use
HK40016900B (en) Therapeutically active compounds and their methods of use
HK40016900A (en) Therapeutically active compounds and their methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190612

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190726

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200525

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200729

R150 Certificate of patent or registration of utility model

Ref document number: 6742905

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250